Although the latter treatments lack the immune-stimulating effects of IL-15, they demonstrate that high avidity targeting of receptors can induce potent responses to a wide range of mesothelin-expressing cancers, not just NSCLC. Here, MSLN is linked to non-small cell lung carcinoma.